for Parkinson’s disease, 1265
Cogentin (see Benztropine)
Colazal (see Balsalazide)
Colchicine, 128, 913, 915
drug interaction, 914t
Colesevelam, 127, 942t
for type 2 diabetes, 1130–1131
Colestipol, 127
Colfosceril, 2170
Colistimethate, 463
for cystic fibrosis, 461t
Colistin, 461t
Colloids, 358–359
Combination vaccines, 1356t
Combined androgen blockade (CAB), 2090
Compazine (see Prochlorperazine)
Conivaptan, 128, 914t
for hyponatremia, 579
Conjugated equine estrogen (Premarin), 1033t
Conjugated estrogen, 1037
Conjugated pneumococcal vaccine (PCV), 1355
Contrave (see Naltrexone/Bupropion)
ConvaTec (see Silver sulfadiazine cream)
Corlanor (see Ivabradine)
Corlopam (see Fenoldopam)
Corticosteroids, 523, 712t, 713t, 721, 899–900, 928, 942t, 1372, 1627, 1639, 1652, 1995–1996
for acne, 827
for acute asthma, 392–393
for acute gout, 913
for adult meningitis, 1377
for AECOPD, 1408
for anaphylaxis, 687–688, 689t
antibiotics with, 819
for bacterial meningitis, 1372
for brain abscess, 1382
for cataracts, 1166–1167
for chronic asthma, 395–397
for CINV, 471
for COPD, 417–418, 422–423
Crohn’s disease, 529
during delivery, 989, 994
for depressive disorders, 1815t
for diabetes, 1146
for drug-induced lupus, 692
drug interaction with smoking, 1907t
for FSGS patients, 628
for hypercalcemia, 589t, 591
hyperglycemia and, 1146
for hyperthyroidism, 1059t
and hypokalemia, 583t
infection and, 1322
for inflammatory bowel disease, 521t, 523
for inflammatory response in CF, 459
intra-articular, 900, 902–904
for JIA, 902–904
management of acute PJP, 1604
for migraine headache, 1240
for MS, 1222, 1228
ophthalmic, 1165–1167, 1166t
for ophthalmopathy, 1067
for PMR and GCA, 925
for PPROM, 994
for psoriasis, 835t, 836–837
for RA, 881, 883
for rhinitis, 442
for SARS, 1660
for septic shock, 372–373
for skin, 813–820, 814–815t, 817t
adverse drug effects of, 816–818
contraindications to, 813, 815
indications for, 813
for systemic lupus erythematosus, 708
teratogenic effects, 973t
therapy for LN, 626
therapy for Wegener granulomatosis, 628
tuberculous meningitis and, 1444
ulcerative colitis, 525–526
Corticotropin, 913
Cosmegen (see Dactinomycin)
Cotrimoxazole, 1720
for aerobic gram-positive cocci, 1326t
for gram-negative aerobes, 1327t
COX-1 (see Cyclooxygenase-1 (COX-1))
COX-2 (see Cyclooxygenase-2 (COX-2))
Creatine, 1265
Crinone (see Progesterone vaginal gel)
Crizotinib, 128, 470t, 2006
Crofelemer, for infectious diarrhea, 1449
Cromolyn, 459
for allergic rhinitis, 434
for rhinitis, 438–439
Cromolyn sodium (Crolom; Nasalcrom), 439t, 440t
Cromolyn sodium ophthalmic, 1165
Crotamiton, 1705t
CRT (see Cardiac resynchronization therapy (CRT))
Crystalloids
composition and properties of, 353t
for hemorrhagic shock, 355
CSA (see Cyclosporine (CSA))
Cubicin (see Daptomycin)
Cyanocobalamin, 914t (see also Vitamin B12
)
for pernicious anemia, 1935
CYC (see Cyclophosphamide (CYC))
Cyclobenzaprine, 1186t, 1194t
Cyclooxygenase-1 (COX-1), 490
Cyclooxygenase-2 (COX-2), 694, 870, 870t, 887, 888t, 889, 913
for systemic lupus erythematosus, 706–707
Cyclophosphamide (CYC), 469t, 470t, 626, 709, 712t, 713t, 917t, 924, 1971, 1977, 1979t, 1987, 1994t,
2004, 2005, 2018, 2037t, 2040t, 2042
for ALL, 2017t
for breast cancer, 2052, 2053
for CLL, 2033
and gonadal toxicity, 1997–1998
and hemorrhagic cystitis, 2021
neurotoxicity of, 1985t
for ophthalmopathy, 1067
for rhabdomyosarcoma, 2010–2011
for T-cell lymphomas, 2020t
teratogenic effects, 973t
therapy for Wegener granulomatosis, 627–628
Cycloserine, for tuberculosis, 1430t
Cyclosporine (CSA), 120t, 127, 214, 528, 928, 942t
for acute UC, 524
for inflammatory bowel disease, 521t
for kidney transplantation, 730–733, 737
for ophthalmopathy, 1067
p. 2297
p. 2298
in organ transplantation, 721–722, 725, 728
for psoriasis, 836t, 840–841
for RA, 883
therapy for LN, 626
CYP2D6 inhibitor, 1774, 1778
CYP3A4 inhibitor, 1743, 1746
and sleep, 1774
Cyproheptadine, for pruritus, 819
Cyproterone, for acne, 829
Cytarabine, 469t, 1985–1986, 1994t, 1996, 1997, 1998, 2018, 2021, 2026, 2028, 2031
adverse effects of, 2028
for aggressive lymphomas, 2043
for ALL, 2017t
for AML, 2025
gonadal toxicity of, 1998
neurotoxicity of, 1985t
for T-cell lymphomas, 2020t
Cytomegalovirus hyperimmune globulin, 743
Cytovene (see Ganciclovir)
D
D-penicillamine, 881
Dabigatran, 128, 187, 1307t
for DVT, 189
for stroke prevention, 178, 317
for warfarin therapy, 200
Dabrafenib, 470t
Dacarbazine (DTIC), 469t, 1978–1979t, 1991t, 2040t
Daclatasvir, for HAV, 1688
Dacogen (see Decitabine (Dacogen))
Dactinomycin (Cosmegen), 469t, 1978–1979t
hepatotoxicity of, 2007–2008
for rhabdomyosarcoma, 2010, 2011
Dalbavancin (Dalvance), 1393
adverse effects of, 1333t
for aerobic gram-positive cocci, 1326t
Dalfampridine, 1223
Dalfopristin/Quinupristin (Synercid), 1325t
adverse effects of, 1333t
Dalteparin, 177t, 188t, 189
LMWH, 656
Dalvance (see Dalbavancin)
Danaparoid, in patients with HIT, 657
Danazol, 120t
adverse effects, 1022
for endometriosis, 1020
for PMDD, 1027
Dantrolene, 1224
Dapagliflozin, 1129–1130
Dapsone, 1604
Daptacel, 1357
Daptomycin (Cubicin), 1326t, 1393
adverse effects of, 1333t
for aerobic gram-positive cocci, 1326t
for CAPD-associated peritonitis, 1476t
dosing of, 1337t
for endocarditis, 1396
enterococcal endocarditis and, 1399
MRSA, 1550
for skin and soft tissue infections, 1549
Darbepoetin alfa (Aranesp), 615–616
for anemia, 1942
Darifenacin, 2251
Darunavir (DRV), 128, 942t, 1579t
Dasabuvir, for HAV, 1689
Dasatinib (Sprycel), 470t, 914t, 1989, 1990, 2031
Daunorubicin (Cerubidine), 469t, 1977, 1979t, 1981t, 1988, 2028
for AML, 2025
and hepatic dysfunction, 1996t
for T-cell lymphomas, 2020t
dDAVP (see desmopressin)
ddl (see Didanosine (ddI))
Decadron (see Dexamethasone)
Decitabine (Dacogen), 469t
Decongestant
for allergic rhinitis, 434, 434t
for rhinitis, 437–438
DEET (see N,N-diethyl-m-toluamide (DEET))
Deferasirox, for vaso-occlusive complications, 1940, 1941
Deferoxamine (DFO)
in iron toxicity, 73
for vaso-occlusive complications, 1940, 1941
Defibrillator, role of, 300
Dehydroepiandrosterone sulfate (DHEAS), 826
DEKAs Plus chewable tablet, 457t
DEKAs Plus liquid, 457t
DEKAs Plus softgel capsules, 457t
Delavirdine (DLV), for HIV, 1580t
∆-9-tetrahydrocannabinol (THC), 1885
Delzicol (see Mesalamine)
Demeclocycline, 579
Demerol (see Meperidine)
Denavir (see Penciclovir cream)
Denileukin diftitox, 469t
Denosumab, 2038, 2277t, 2284–2285
androgen deprivation therapy, 2097
for prostate cancer, 2096
Deoxycholate, for sepsis, 2186t
Depacon, 1299
Depo-Provera, 947–948
Depot medroxyprogesterone acetate (DMPA), 1021
Desferal, in iron toxicity, 73
Desiccated thyroid, 1048–1049
Desipramine (see also Antidepressants)
for depressive disorders, 1819t, 1821t
Desloratadine (Clarinex), 433t
for rhinitis, 437
Desmopressin (dDAVP), 647
Desogestrel, 936–938t, 945
Desvenlafaxine (Pristiq)
for depressive disorders, 1819t, 1821t
for diabetes, 2226t
for serotonin, 1826
for vasomotor symptoms, 1036t
Dexamethasone (Decadron), 472t, 475–476, 994, 1639, 2036, 2037t, 2038
for ALL, 2017t
for bacterial meningitis, 1372–1373
for BPD, 2175
for PCOS, 1013
for PONV, 478t
for prostate cancer, 2094
for T-cell lymphomas, 2020t
Dexedrine (see Dextroamphetamine)
Dexlansoprazole, 483t, 1216t
PPI, 484, 485
Dexmedetomidine, 1213–1214
for pediatric intubation, 2200t
Dexmethylphenidate, for ADHD, 1867t
Dexrazoxane, 469t, 1980, 1981t, 1988–1989
Dextran component, 614
D
e
x
t
r
o
a
m
p
h
e
t
a
m
i
n
e
(
D
e
x
e
d
ri
n
e
)
,
4
6
8
t
,
1
7
7
8
D
e
x
t
r
o
m
e
t
h
o
rp
h
a
n
,
1
2
2
4
,
1
2
3
2
dis
s
o
c
ia
t
iv
e
drug
,
1
8
8
5
quinidin
e
c
o
mb
in
a
t
io
n
,
fo
r
a
g
it
a
t
e
d
b
e
h
a
v
io
r
s
,
2
2
4
3
D
e
x
t
r
o
rp
h
a
n
,
1
8
8
5
D
e
x
t
r
o
s
e
,
6
6
1
,
6
6
3
,
7
9
2
D
F
O
(
s
e
e
D
e
fe
r
o
x
a
m
i
n
e
(
D
F
O
)
)
D
H
A
(
s
e
e
D
i
c
o
s
o
h
e
x
a
n
o
i
c
a
c
i
d
(
D
H
A
)
)
D
H
A
P
,
fo
r
a
g
g
r
e
s
s
i
v
e
l
y
m
p
h
o
m
a
s
,
2
0
4
1
–
2
0
4
2
D
H
E
A
S
(
s
e
e
D
e
h
y
d
r
o
e
p
i
a
n
d
r
o
s
t
e
r
o
n
e
s
u
l
fa
t
e
(
D
H
E
A
S
)
)
D
H
T
(
s
e
e
D
i
h
y
d
r
o
t
e
s
t
o
s
t
e
r
o
n
e
(
D
H
T
)
)
D
i
az
e
p
a
m
,
5
6
5
,
9
8
8
,
1
1
8
6
t
,
1
7
3
7
t
,
1
7
4
2
,
1
7
4
6
,
2
1
3
1
t
fo
r
A
ka
th
is
ia
,
1
8
0
0
t
drug
int
e
r
a
c
t
io
n
w
ith
s
mo
kin
g
,
1
9
0
7
t
fe
b
r
ile
s
e
izur
e
s
a
n
d
,
1
2
9
5
P
C
P
-
in
du
c
e
d
s
e
izur
e
s
,
1
8
8
5
fo
r
p
e
dia
tr
ic
intub
a
t
io
n
,
2
1
9
9
t
in
S
E
,
1
2
9
9
fo
r
T
a
r
div
e
dy
s
kin
e
s
ia
,
1
8
0
1
D
i
b
e
n
z
o
x
az
e
p
i
n
e
,
1
7
8
9
t
D
i
b
e
n
z
o
yl
m
e
t
h
a
n
e
s
,
8
4
9
t
,
8
5
2
D
i
c
l
e
g
i
s
,
9
7
5
D
i
c
l
o
fe
n
a
c
,
5
5
,
8
7
0
t
,
8
7
1
,
8
8
7
,
8
8
8
t
,
1
1
8
7
t
D
i
c
l
o
fe
n
a
c
g
e
l
,
8
6
9
D
i
c
l
o
fe
n
a
c
p
a
t
c
h
,
8
6
9
D
i
c
l
o
fe
n
a
c
t
o
p
i
c
a
l
s
o
l
u
t
i
o
n
,
8
6
9
D
i
c
l
o
x
a
c
i
l
l
i
n
,
6
4
5
,
1
3
2
5
t
fo
r
s
kin
a
n
d
s
o
ft
t
is
s
u
e
in
fe
c
t
io
n
s
,
1
5
4
7
D
i
c
o
s
o
h
e
x
a
n
o
i
c
a
c
i
d
(
D
H
A
)
,
1
2
5
–
1
2
6
D
i
c
y
c
l
o
m
i
n
e
(
s
e
e
A
n
t
i
s
p
a
s
m
o
d
i
c
s
)
D
i
d
a
n
o
s
i
n
e
(
d
d
I
)
,
9
1
8
t
fo
r
H
I
V
,
1
5
7
8
t
fo
r
H
I
V
in
la
b
o
r
,
9
9
6
fo
r
H
I
V
-
r
e
la
t
e
d
a
n
e
mia
,
1
9
4
4
D
i
e
n
o
g
e
s
t
,
9
3
8
t
D
i
e
t
h
yl
c
a
rb
a
m
azi
n
e
,
fo
r
a
m
e
b
i
c
l
i
v
e
r
a
b
s
c
e
s
s
,
1
7
0
4
t
D
i
e
t
h
yl
p
r
o
p
i
o
n
,
7
6
2
D
i
e
t
h
yl
s
t
i
l
b
e
s
t
r
o
l
,
t
e
r
a
t
o
g
e
n
i
c
e
ffe
c
t
s
,
9
7
3
t
D
i
fi
c
i
d
(
s
e
e
F
i
d
a
x
o
m
i
c
i
n
)
D
i
fl
u
c
a
n
(
s
e
e
F
l
u
c
o
n
az
o
l
e
)
D
i
fl
u
n
i
s
a
l
,
8
7
0
t
D
i
g
i
t
a
l
i
s
(
D
i
g
o
x
i
n
)
,
1
2
8
,
2
1
4
,
4
8
4
,
6
6
5
,
9
1
4
t
,
2
1
3
1
t
fo
r
A
F
,
3
1
2
–
3
1
3
do
s
e
s
o
f,
2
9
1
p. 2
2
9
8
p. 2
2
9
9
drug
int
e
r
a
c
t
io
n
s
,
2
9
3
t
e
ffe
c
t
o
n
mo
r
t
a
lity
,
2
9
0–
2
9
1
e
ffic
a
c
y
o
f,
2
9
0
fo
r
H
F
,
2
6
8
,
2
7
1
a
n
d
hyp
e
r
ka
le
mia
,
5
8
5
fo
r
hyp
e
r
thyr
o
idis
m
,
1
0
5
7
monitoring parameters, 291
serum drug concentrations, 291
sex differences in response to, 291
toxicity, 292
withdrawal trials, 290
Digitalis glycosides, for HF, 290–293
Digoxin (see Digitalis)
Dihydroergotamine, 1239, 1240
Dihydropyridine calcium-channel blockers, for vascular dementia, 2242
Dihydrotestosterone (DHT), 826
Dilaudid (see Hydromorphone)
Diloxanide furoate, 1706
for amebicides, 1703t
Diltiazem, 120t, 128, 155–156, 214, 609, 1061, 2261t
for AF, 314
for HF, 275
for HFpEF, 271, 272
in patients with CKD, 617
for thyroid storm, 1067
Dimenhydrinate (Dramamine), 468t
for NVP, 975, 976t
Dimethyl fumarate, for MS, 1222, 1228
Dinoprostone cervical gel, 989–990
Dinoprostone slow-release insert (Cervidil), 989
Dinutuximab, 469t
Dioxybenzone, 849t, 852
Dipalmitoylphosphatidylcholine (DPPC), 2170
Dipentum (see Olsalazine)
Dipeptidyl peptidase-4 inhibitors (DPP-4)
adverse effects of, 1128
contraindications and precautions of, 1128
for diabetes, 2225
dosage and clinical use, 1128–1129
drug interactions, 1128
efficacy of, 1128
mechanism of action, 1127
pharmacokinetics of, 1127–1128
Diphenhydramine (Benadryl), 433t, 1776
for Akathisia, 1800t
for nocturnal leg cramps, 173
for NVP, 975, 976t
for Parkinsonism, 1799
for sleep, 1861
Diphenoxylate, 536
Diphenoxylate/atropine, 1449
Diphtheria, tetanus, and acellular pertussis (DTaP), 1355
vaccines, 1357
Dipyridamole, 1307t, 1314
Direct oral anticoagulants (DOACs), 178
advantages of, 187
dosing for AF and VTE, 179t
drug interactions with, 179t
for management of PE, 191
pharmacokinetic and pharmacodynamics properties of, 178t
for stroke prevention, 194
for VTE treatment, 194
Direct thrombin inhibitors
for heparin-induced thrombocytopenia, 178
injectable, 180t
Direct vasodilators, for hypertension, 140
Dirithromycin (Dynabac), 1325t
Diskus, for chronic asthma, 394, 396
Disopyramide
for HF, 275
for tachycardia, 1802
Disulfiram, alcohol withdrawal, 1897, 1898
Diuretics, 580
acetazolamide, 581
adverse effects of, 277–278
and azotemia, 277
and BNP, 278
combination therapy of, 279
for dysmenorrhea, 1015
for HF, 270
for hypertension, 140, 147–151
and hyperuricemia, 278
and hypokalemia, 150, 278
hypomagnesemia and, 151, 278
and hyponatremia, 151, 277–278, 581
loop, 580
and metabolic alkalosis/acidosis, 581
monitoring parameters with, 280t
for nephrotic edema, 574
osmotic, 581
for PMS, 1025
potassium-sparing, 580–581
thiazide, 580, 2261t
Divalproex, 1242, 1292, 1849t
Divigel (see Estradiol gel; Estradiol topical emulsion/gel/solution)
DLV (see Delavirdine (DLV))
DMARD, for RA, 891–899
DMPA (see Depot medroxyprogesterone acetate (DMPA))
DOACs (see Direct oral anticoagulants (DOACs))
Dobutamine, 212, 2207t, 2208
in cardiac failure, 363–364, 363t
for cardiogenic shock, 363–364
for HF, 271, 298
for septic shock, 371–372
for tachycardia, 365
Docetaxel, 469t, 475, 1978t, 1981t, 1983t, 1990
and hepatic dysfunction, 1996t
for NSCLC, 2062t, 2064t
peripheral nerve toxicity of, 1986
for prostate cancer, 2094
Docosanol cream (Abreva), 1650
Dofetilide
for AF, 316–317
for SuVT, 325
for tachycardia, 1802
for WPW, 320
Dolasetron (Anzemet), 472t
for PONV, 478t
Donepezil
for Alzheimer’s disease, 2238
for vascular dementia, 2242
Dopamine, 641, 689t, 1224, 2207t, 2208
for cardiac performance, 362–363, 363t
for cardiogenic shock, 362–363
GERD and, 503t
for HF, 271, 298
for hyperprolactinemia, 1802
for mild hypotension, 363–364
for NVP, 976t
for septic shock, 371–372
for Tardive dyskinesia, 1801
Dopamine agonists, 1252–1253, 1261–1262
adverse effects of, 1255–1256
dosage of, 1255
for Parkinson’s disease, 1253–1256
Doral (see Quazepam)
Doribax (see Doripenem)
Doripenem (Doribax), 1326t, 1371
for skin and soft tissue infections, 1550
Dornase alfa, 458–459
Dorzolamide (Trusopt), 1152
Doxazosin, 157t, 2256, 2261t
for BPH, 2256
in patients with CKD, 617
Doxepin (Silenor)
for depressive disorders, 1819t
for pruritus, 819
for treatment of insomnia, 1767t
Doxercalciferol, 622
Doxorubicin, 469t, 1977, 1978–1979t, 1978t, 1979, 1981t, 1983t, 1987–1988, 2003, 2005, 2040t, 2042
for ALL, 2017t
for breast cancer, 2052, 2053
and cardiomyopathy, 1987–1988
cardiotoxicity of, 2007
gonadal toxicity of, 1998
for HL, 2041
for osteosarcoma, 2008
for rhabdomyosarcoma, 2010, 2011
for T-cell lymphomas, 2020t
Doxycycline, 927, 942t, 1325t, 1698t, 1720, 1723
for cellulitis, 645
for acne, 828, 829
for COPD, 418
dosing of, 1337t
for lymphogranuloma venereum, 1515
for malaria prophylaxis, 49
for PID, 1512–1513t
for skin and soft tissue infections, 1547, 1552
in UTI, 1501
for HGA, 1726
for HME, 1726
fo
r
L
yme
dis
e
a
s
e
,
1
7
2
0
fo
r
R
M
S
F
,
1
7
2
5
fo
r
T
B
R
F
,
1
7
2
3
fo
r
tula
r
e
mia
,
1
7
2
4
D
o
x
yl
a
m
i
n
e
,
1
7
7
6
fo
r
N
V
P
,
9
7
5
,
9
7
6
t
p. 2
2
9
9
p. 2
3
0
0
D
P
P
-
4
(
s
e
e
D
i
p
e
p
t
i
d
yl
p
e
p
t
i
d
a
s
e
-
4
i
n
h
i
b
i
t
o
r
s
(
D
P
P
-
4
)
)
D
P
P
C
(
s
e
e
D
i
p
a
l
m
i
t
o
yl
p
h
o
s
p
h
a
t
i
d
yl
c
h
o
l
i
n
e
(
D
P
P
C
)
)
D
r
a
m
a
m
i
n
e
(
s
e
e
D
i
m
e
n
h
y
d
ri
n
a
t
e
)
D
r
o
n
a
b
i
n
o
l
(
M
a
ri
n
o
l
)
,
4
7
2
t
,
1
2
0
4
D
r
o
n
e
d
a
r
o
n
e
,
1
2
0
t
fo
r
A
F
,
3
1
6–
3
1
7
fo
r
H
F
,
2
7
5
D
r
o
p
e
ri
d
o
l
(
I
n
a
p
s
i
n
e
)
,
4
7
2
t
fo
r
N
V
P
,
9
7
No comments:
Post a Comment
اكتب تعليق حول الموضوع